Defining the success of cardiac gene therapy: How can nuclear imaging contribute?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 5, 2003, Pages 757-771

  Avril, Norbert ^a   Bengel, Frank M ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gene therapy; Myocardium; Nuclear cardiology; Positron emission tomography; Reporter gene

Indexed keywords

ANGIOGENIC FACTOR; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR KINASE INHIBITORY PEPTIDE; BETA GALACTOSIDASE; CD40 IMMUNOGLOBULIN; DESMOPRESSIN; FIBROBLAST GROWTH FACTOR; GANCICLOVIR; GLUTATHIONE PEROXIDASE; HEAT SHOCK PROTEIN 70; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; NAKED DNA; NITRIC OXIDE SYNTHASE; PROTEIN BCL 2; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; PROTEIN P21; PROTEIN P35; PROTEIN SERCA2A; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASOPRESSIN V2 RECEPTOR; VIRUS VECTOR;

ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW; CARDIOVASCULAR DISEASE; CELL DEATH; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TISSUE LEVEL; ECHOCARDIOGRAPHY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE LOCATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GRAFT REJECTION; HEART; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HERPES SIMPLEX VIRUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMAGING; INNERVATION; ISOTOPE LABELING; LEG ISCHEMIA; METABOLISM; MOLECULAR PROBE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MEDICINE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; REPERFUSION INJURY; REPORTER GENE; RESTENOSIS; SCINTIANGIOGRAPHY; TRANSGENE; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0038245113     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1100-2     Document Type: Article

References (103)

1. Isner JM. Myocardial gene therapy. Nature 2002; 415:234-239.
2. Nabel EG. Gene therapy for cardiovascular disease. Circulation 1995; 91:541-548.
3. Welsh S, Kay SA. Reporter gene expression for monitoring gene transfer. Curr Opin Biotechnol 1997; 8:617-622.
4. Buchholz CJ, Stitz J, Cichutek K. Retroviral cell targeting vectors. Curr Opin Mol Ther 1999; 1:613-621.
5. Lusky M, Christ M, Rittner K, et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 1998; 72:2022-2032.
6. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3:306-312.
7. Wolff JA, Ludtke JJ, Acsadi G, et al. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992; 1:363-369.
8. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990; 249:1285-1288.
9. Binley K, Iqball S, Kingsman A, et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther 1999; 6:1721-1727.
10. De Geest B, Van Linthout S, Lox M, et al. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum Gene Ther 2000; 11:101-112.
11. Guzman RJ, Lemarchand P, Crystal RG, et al. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res 1993; 73:1202-1207.
12. Barr E, Carroll J, Kalynych AM, et al. Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther 1994; 1:51-58.
13. Boekstegers P, von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther 2000; 7:232-240.
14. Fromes Y, Salmon A, Wang X, et al. Gene delivery to the myocardium by intrapericardial injection. Gene Ther 1999; 6:683-688.
15. Hajjar RJ, Schmidt U, Matsui T, et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 1998; 95:5251-5256.
16. Maurice JP, Hata JA, Shah AS, et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest 1999; 104:21-29.
17. Donahue JK, Kikkawa K, Johns DC, et al. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci USA 1997; 94:4664-4668.
18. Marshall DJ, Palasis M, Lepore JJ, et al. Biocompatibility of cardiovascular gene delivery catheters with adenovirus vectors: an important determinant of the efficiency of cardiovascular gene transfer. Mol Ther 2000; 1:423-429.
19. Schumacher B, Hannekum A, Pecher P. Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease. Z Kardiol 2000; 7:23-30.
20. Takeshita S, Weir L, Chen D, et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 1996; 227:628-635.
21. Takeshita S, Tsurumi Y, Couffinahl T, et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest 1996; 75:487-501.
22. Mack CA, Patel SR, Schwarz EA, et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998; 115:168-176; discussion 176-177.
23. Tio RA, Tkebuchava T, Scheuermann TH, et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999; 10:2953-2960.
24. Vincent KA, Shyu KG, Luo Y, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000; 102:2255-2261.
25. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98:2800-2804.
26. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100:468-474.
27. Yoshida T, Watanabe M, Engelman DT, et al. Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia reperfusion injury. J Mol Cell Cardiol 1996; 28:1759-1767.
28. Yoshida T, Maulik N, Engelman RM, et al. Glutathione peroxidase knockout mice are susceptible to myocardial ischemia reperfusion injury. Circulation 1997; 96:II-216-II-220.
29. Jayakumar J, Suzuki K, Khan M, et al. Gene therapy for myocardial protection: transfection of donor hearts with heat shock protein 70 gene protects cardiac function against ischemia-reperfusion injury. Circulation 2000; 102:III302-III306.
30. Hajjar RJ, Kang JX, Gwathmey JK, et al. Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation 1997; 95:423-429.
31. Steg PG, Tahlil O, Aubailly N, et al. Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation 1997; 96:408-411.
32. Smith RC, Wills KN, Antelman D, et al. Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation 1997; 96:1899-1905.
33. Luo Z, Sata M, Nguyen T, et al. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation 1999; 99:1776-1779.
34. Van Belle E, Maillard L, Tio FO, et al. Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation. Biochem Biophys Res Commun 1997; 235:311-316.
35. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92:1137-1141.
36. Mann MJ, Gibbons GH, Hutchinson H, et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A 1999; 96:6411-6416.
37. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354:1493-1498.
38. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999; 100:2308-2311.
39. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000; 97:793-798.
40. He H, Meyer M, Martin JL, et al. Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility. Circulation 1999; 100:974-980.
41. Akhter SA, Skaer CA, Kypson AP, et al. Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A 1997; 94:12100-12105.
42. Shah AS, Lilly RE, Kypson AP, et al. Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart: prospects for molecular ventricular assistance. Circulation 2000; 101:408-414.
43. Weig HJ, Laugwitz KL, Moretti A, et al. Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-guided injection or transcoronary delivery. Circulation 2000; 101:1578-1585.
44. Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999; 97:189-198.
45. Kirshenbaum LA, de Moissac D. The bcl-2 gene product prevents programmed cell death of ventricular myocytes. Circulation 1997; 96:1580-1585.
46. Laugwitz KL, Moretti A, Weig HJ, et al. Blocking caspase-activated apoptosis improves contractility in failing myocardium. Hum Gene Ther 2001; 12:2051-2063.
47. Buerke M, Murohara T, Skurk C, et al. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 1995; 92:8031-8035.
48. Ardehali A, Reddy R, Laks H. Gene therapy and heart transplantation. Expert Opin Investig Drugs 2000; 9:1021-1027.
49. Lee J, Laks H, Drinkwater DC, et al. Cardiac gene transfer by intracoronary infusion of adenovirus vector-mediated reporter gene in the transplanted mouse heart. J Thorac Cardiovasc Surg 1996; 111:246-252.
50. Iwata A, Sai S, Nitta Y, et al. Liposome-mediated gene transfection of endothelial nitric oxide synthase reduces endothelial activation and leukocyte infiltration in transplanted hearts. Circulation 2001; 103:2753-2759.
51. Guillot C, Guillonneau C, Mathieu P, et al. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol 2002; 168:1600-1609.
52. Chen SJ, Rader DJ, Tazelaar J, et al. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol Ther 2000; 2:256-261.
53. Kozarsky KF, Donahee MH, Glick JM, et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 2000; 20:721-727.
54. Tangirala RK, Tsukamoto K, Chun SH, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100:1816-1822.
55. Chao J, Zhang JJ, Lin KF, et al. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahsalt-sensitive rats. Hum Gene Ther 1998; 9:21-31.
56. Dobrzynski E, Wang C, Chao J, et al. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 2000; 36:995-1001.
57. Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 1997; 30:307-313.
58. Martens JR, Reaves PY, Lu D, et al. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc Natl Acad Sci U S A 1998; 95:2664-2669.
59. Bengel FM, Schwaiger M. Nuclear medicine studies of the heart. Eur Radiol 1998; 8:1698-1706.
60. Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001; 103:2138-2143.
61. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105:2012-2018.
62. Henry TD, Annex BH, Azrin MA, et al. Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis [abstract]. Circulation 1999; 100 (Suppl I):I-476.
63. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002; 105:788-793.
64. Bengel FM, Permanetter B, Ungerer M, et al. Non-invasive estimation of myocardial efficiency using positron emission tomography and carbon-11 acetate - comparison between the normal and failing human heart. Eur J Nucl Med 2000; 27:319-326.
65. Beanlands RS, Nahmias C, Gordon E, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation 2000; 102:2070-2075.
66. 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation 1993; 87:1169-1178.
67. Ungerer M, Hartmann F, Karoglan M, et al. Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation 1998; 97:174-180.
68. Schafers M, Dutka D, Rhodes CG, et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 1998; 82:57-62.
69. Blankenberg F, Narula J, Strauss HW. In vivo detection of apoptotic cell death: a necessary measurement for evaluating therapy for myocarditis, ischemia, and heart failure. J Nucl Cardiol 1999; 6:531-539.
70. Narula J, Petrov A, Bianchi C, et al. Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments. Circulation 1995; 92:474-484.
71. Ohtsuki K, Hayase M, Akashi K, et al. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: an autoradiographic study. Circulation 2001; 104:203-208.
72. 99mTc-labeled adenovirus knob (serotype 5). Gene Ther 1998; 5:798-808.
73. 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer 2000; 83:232-238.
74. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94:715-725.
75. Sweeney TJ, Mailander V, Tucker AA, et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 1999; 96:12044-12049.
76. Weissleder R, Tung CH, Mahmood U, et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999; 17:375-378.
77. Hogemann D, Josephson L, Weissleder R, et al. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug Chem. 2000; 11:941-946.
78. Louie AY, Huber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000; 18:321-325.
79. Stegman LD, Rehemtulla A, Beattie B, et al. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 1999; 96:9821-9826.
80. Freeman SM, Whartenby KA, Freeman JL, et al. In situ use of suicide genes for cancer therapy. Semin Oncol 1996; 23:31-45.
81. Saito Y, Rubenstein R, Price RW, et al. Diagnostic imaging of herpes simplex virus encephalitis using a radiolabeled antiviral drug: autoradiographic assessment in an animal model. Ann Neurol 1984; 15:548-558.
82. Gambhir SS, Herschman HR, Cherry SR, et al. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2000; 2:118-138.
83. Tjuvajev JG, Stockhammer G, Desai R, et al. Imaging the expression of transfected genes in vivo. Cancer Res 1995; 55:6126-6132.
84. Tjuvajev JG, Finn R, Watanabe K, et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 1996; 56:4087-4095.
85. Tjuvajev JG, Avril N, Oku T, et al. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 1998; 58:4333-4341.
86. Tjuvajev JG, Chen SH, Joshi A, et al. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res 1999; 59:5186-5193.
87. Haubner R, Avril N, Hantzopoulos PA, et al. In vivo imaging of herpes simplex virus type 1 thymidine kinase gene expression: early kinetics of radiolabelled FIAU. Eur J Nucl Med 2000; 27:283-291.
88. 18F]-FHPG): a potential imaging agent of viral infection and gene therapy using PET. Nucl Med Biol 1996; 23:787-792.
89. 18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol 1998; 25:175-180.
90. Gambhir SS, Barrio JR, Wu L, et al. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med 1998; 39:2003-2011.
91. 125I]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. Eur J Nucl Med 2001; 28:721-729.
92. Gambhir SS, Bauer E, Black ME, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 2000; 97:2785-2790.
93. Iyer M, Wu L, Carey M, et al. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA 2001; 98:14595-14600.
94. Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci USA 2001; 98:9300-9305.
95. Jacobs A, Voges J, Reszka R, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 2001; 358:727-729.
96. MacLaren DC, Gambhir SS, Satyamurthy N, et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999; 6:785-791.
97. 188Re. J Nucl Med 2000; 41:887-895.
98. Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59:661-668.
99. Bengel FM, Anton M, Avril N, et al. Uptake of radiolabeled 2'-fluoro-2'-deoxy-5-iodo-1-beta-D-arabinofuranosyluracil in cardiac cells after adenoviral transfer of the herpesvirus thymidine kinase gene: the cellular basis for cardiac gene imaging. Circulation 2000; 102:948-950.
100. Wu JC, Inubushi M, Sundaresan G, et al. Optical imaging of cardiac reporter gene expression in living rats. Circulation 2002; 105:1631-1634.
101. Wu JC, Inubushi M, Sundaresan G, et al. Positron emission tomography imaging of cardiac reporter gene expression in living rats. Circulation 2002; 106:180-183.
102. Inubushi M, Wu J, Gambhir SS, et al. PET reporter gene expression imaging in rat myocardium. Circulation 2003; 107 (in press): DOI 10.1161/01.CIR.0000044385.60972.AE.
103. Bengel F, Anton M, Haubner R, et al. In vivo imaging of transgene expression using the herpesviral thymidinekinase reporter gene (HSV1-tk) and radiolabeled FIAU in the rat and pig heart (abstract). Circulation. 2002; 106 (Suppl II):II-331.